Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21523859 | 0.87 | P2RY14 (0.45) | OPRM1OPRL1OPRK1OPRD1CES1 | |
| Trifluoroacetic Acid SCHEMBL31083998 | 0.85 | P2RY14 (0.46) | OPRM1OPRL1OPRK1OPRD1CES1 | |
| Trifluoroacetic Acid SCHEMBL17080482 | 0.85 | DRD2 (0.37) | OPRM1DRD2 | |
| Trifluoroacetic Acid SCHEMBL28508438 | 0.85 | DRD2 (0.53) | OPRM1OPRL1OPRK1OPRD1DRD2 | |
| SCHEMBL1668502 | 0.84 | OPRM1 (0.48) | OPRM1OPRL1OPRK1OPRD1DRD2 | |
| Hydrochloric Acid SCHEMBL5901298 | 0.82 | OPRM1 (0.46) | OPRM1OPRL1OPRK1OPRD1DRD2 | |
| Trifluoroacetic Acid SCHEMBL31083966 | 0.81 | OPRM1 (0.44) | OPRM1OPRL1OPRK1OPRD1HSD11B1 | |
| Trifluoroacetic Acid SCHEMBL15212228 | 0.77 | P2RY14 (0.38) | OPRM1OPRL1OPRK1OPRD1CES1 | |
| Trifluoroacetic Acid SCHEMBL31084060 | 0.76 | OPRM1 (0.39) | OPRM1OPRL1OPRK1OPRD1DRD2 | |
| Tert-Butyl Formate SCHEMBL27846026 | 0.73 | TDP1 (0.41) | OPRM1OPRL1OPRK1OPRD1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342194-B1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2018-08-08 | — | — | EP | disclosed |
| CN-104387372-B | Oxo azetidine derivatives, preparation method and its purposes in human medical and cosmetics | 盖尔德马研究及发展公司 | 2018-06-26 | — | — | CN | disclosed |
| EP-3321257-A1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9868746-B2 | Substituted 5-aminothieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2817295-B1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9630949-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-04-25 | — | — | US | disclosed |
| US-20170022216-A1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2017-01-26 | — | — | US | disclosed |
| US-9493481-B2 | Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2016-11-15 | — | — | US | disclosed |
| CN-104387372-A | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV | 2015-03-04 | — | — | CN | disclosed |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-12 | — | — | US | disclosed |
| EP-2817295-A1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2014-12-31 | — | — | EP | disclosed |
| US-8871187-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereon in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-28 | — | — | US | disclosed |
| WO-2013126856-A1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2013-08-29 | — | — | WO | disclosed |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
| CN-102203081-A | Oxoazetidine derivatives, method for the production thereof and use thereof in human medicine and cosmetics | GALDERMA RES & DEV | 2011-09-28 | — | — | CN | disclosed |
| EP-2342194-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010052253-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | CYP2D6, CYP51A1, CYP2C19 | OPRM1 686/4885OPRL1 1364/4885OPRK1 1054/4885 |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | CYP51A1, TYR, CYP2C19 | OPRM1 495/4885OPRL1 1166/4885OPRK1 729/4885 |
| US-20170022216-A1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM5, CHRM4, CHRM3 | OPRM1 81/4885OPRL1 92/4885OPRK1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.